Is Our Data Any Good?


We are usually so excited about our projects that as soon as we get data from a new experiment, we can't wait to analyze it. We want to find out as soon as possible whether it supports our hypothesis or which genes play a role in our favorite process. It's not until the answer is unexpected or a "maybe" that we generally start to question the quality of our analytical inputs. But as we get a bit more experienced and more systematic, we're trying to make quality control preliminary steps for analysis rather than just part of the post--mortem examination.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.